The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Oct 16, 2026
Snapshot (as of Oct 16, 2026): Novo Nordisk A/S (NVO) pays a $11.70 annual dividend, yielding 4.58% at $39.22/share. Next ex-dividend date 2026-08-17. 6 consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 4.58%
Annual Dividend: $11.70 per share
Payout Ratio: 43.1%
Ex-Dividend Date: 2026-08-17
Dividend Frequency: annually
Sector: Healthcare
Years of Dividend History: 45
Novo Nordisk A/S dividend investors are looking at a pharmaceutical company built around diabetes and obesity care, with products ranging from insulin pens to the Dose Check app for insulin dosage guidance. The current yield sits at 4.37%, well above what NVO has historically offered. Trailing annual payments total $11.70 per share, paid semi-annually, with the next ex-dividend date on August 17, 2026. A beta of 0.349 points to low price volatility, which suits income investors who prioritize steady payouts over share price swings.
Novo Nordisk A/S pays out 44.6% of earnings as dividends, a payout ratio classified as moderate (40–60%). That level leaves meaningful earnings retained within the business, and NVO's two core divisions, Diabetes and Obesity Care and Rare Disease, address chronic and rare conditions that generate recurring demand for therapies and medical devices. Novo Nordisk A/S dividend safety faces its most credible pressure from currency translation, given the company's broad international footprint spanning Europe, North America, Asia, and the Middle East, which can cause reported per-share dividend amounts to fluctuate even when the underlying business performs well.
Novo Nordisk A/S dividend history shows a CAGR of 18.5% per year from 2010 to 2025. Per-share payments grew from $0.1359 to $1.7269 over that span (2026 is a partial year and excluded from this calculation). The largest single-year jump in the window was 93.4% in 2016, though the data also contains at least one year-over-year decline exceeding 5%, a reminder that the growth path has not been linear.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +29.2% | $0.80 (2022) | $1.73 (2025) |
| 5-Year | +21.6% | $0.65 (2020) | $1.73 (2025) |
| 10-Year | +16.8% | $0.36 (2015) | $1.73 (2025) |
Novo Nordisk A/S fits dividend investors who want meaningful current income from a pharmaceutical business anchored in chronic disease treatment. The yield is classified as high (above 4%), and at 4.37% it sits well above the 5-year average of 2.65%, meaning today's buyers are locking in a historically elevated entry yield. The 44.6% payout ratio supports that yield without stretching the balance sheet. The trade-off is that six consecutive years of increases is a relatively short streak, and the history table shows past declines, so the growth record is impressive in magnitude but not unbroken in direction.
| Payment Date | Amount per Share |
|---|---|
| 2026-08-17 | $0.5792 |
| 2026-03-30 | $1.2174 |
| 2025-08-18 | $0.5843 |
| 2025-03-31 | $1.1426 |
| 2024-08-16 | $0.5169 |
| 2024-03-22 | $0.9293 |
| 2023-08-18 | $0.4382 |
| 2023-03-24 | $0.5903 |
| 2022-08-12 | $0.2889 |
| 2022-03-25 | $0.5112 |
| Year | Total Dividends |
|---|---|
| 2026 | $1.7966 |
| 2025 | $1.7269 |
| 2024 | $1.4462 |
| 2023 | $1.0285 |
| 2022 | $0.8001 |
Project income from NVO with the NVO dividend calculator or track your full portfolio with the dividend tracker.